COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,398 Articles (22,816 medRxiv, 8,582 bioRxiv)

Most recent first Previous |  Page 1067: Articles 10661-10670  | Next

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
Syed, A. M., Ciling, A., Khalid, M. M., Sreekumar, B., Kumar, G. R., Silva, I., Milbes, B., Kojima, N., Hess, V., Shacreaw, M., Lopez, L., Brobeck, M., Turner, F., Spraggon, L., Taha, T. Y., Tabata, T., Chen, I. P., Ott, M., Doudna, J. A.
10.1101/2021.12.20.21268048 — Posted: 2021-12-21
Mutational analysis of SARS-CoV-2. ORF8 and the evolution of the Delta and Omicron variants.
Trieu, G., Trieu, V. N.
10.1101/2021.12.19.21268069 — Posted: 2021-12-21
South African Population Immunity and Severe Covid-19 with Omicron Variant
Madhi, S., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A., Blumberg, L., Welch, R., Ngorima-Mabhena, N., Mutevedzi, P. C.
10.1101/2021.12.20.21268096 — Posted: 2021-12-21 Discussion: Onsite
Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
Lee, T. C., Vigod, S., Bortolussi-Courval, E., Hanula, R., Boulware, D. R., Lenze, E. J., Reiersen, A. M., McDonald, E. G.
10.1101/2021.12.17.21268008 — Posted: 2021-12-21
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant
Dolzhikova, I. V., Iliukhina, A. A., Kovyrshina, A. V., Kuzina, A. V., Gushchin, V. A., Siniavin, A. E., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Megeryan, M. M., Dzharullaeva, A. S., Erokhova, A. S., Izhaeva, F. M., Grousova, D. M., Botikov, A. G., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Logunov, D. Y., Gintsburg, A. L.
10.1101/2021.12.17.21267976 — Posted: 2021-12-21
Government messaging about COVID-19 vaccination in Canada and Australia: a Narrative Policy Framework study
Saich, F., Martiniuk, A.
10.1101/2021.12.19.21268042 — Posted: 2021-12-21
Passage of SARS-CoV-2 in cells expressing human and mouse ACE2 selects for mouse-adapted and ACE2-independent viruses
Yan, K., Dumenil, T., Le, T. T., Tang, B., Bishop, C., Suhrbier, A., Rawle, D. J.
10.1101/2021.12.16.473063 — Posted: 2021-12-21
Context-specific emergence and growth of the SARS-CoV-2 Delta variant
McCrone, J. T., Hill, V., Bajaj, S., Evans Pena, R., Lambert, B. C., Inward, R., Bhatt, S., Volz, E., Ruis, C., Dellicour, S., Baele, G., Zarebski, A. E., Sadilek, A., Wu, N., Schneider, A., Ji, X., Raghwani, J., Jackson, B., Colquhoun, R., O'Toole, A., Peacock, T. P., Twohig, K., Thelwall, S., Dabrera, G., Myers, R., The COVID-19 genomics UK (COG-UK) consortium, , Faria, N. R., Huber, C., Bogoch, I. I., Khan, K., Plessis, L. d., Barrett, J. C., Aanensen, D. M., Barclay, W. S., Chand, M., Connor, T., Loman, N. J., Suchard, M. A., Pybus, O. G., Rambaut, A., Kraemer, M. U. G.
10.1101/2021.12.14.21267606 — Posted: 2021-12-21
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., Heath, S. L., Levine, A. C., Meisenberg, B. R., Spivak, E. S., Anjan, S., Huaman, M. A., Blair, J. E., Currier, J. S., Paxton, J. H., Gerber, J. M., Petrini, J. R., Broderick, P. B., Rausch, W., Cordisco, M. E., Hammel, J., Greenblatt, B., Cluzet, V. C., Cruser, D., Oei, K., Abinante, M., Hammit, L. L., Suttcliffe, C. G., Forthal, D. N., Zand, M. S., Cachay, E. R., Raval, J. S., Kassaye, S. G., Foster, C., Roth, M., Marshall, C. E., Yarava, A., Lane, K., McBee, N. A., Gawad, A. L., Karlen, N., Singh, A., Ford, D. E., Jabs, D. A., Appel, L. J., Shade, D. M., Ehrhardt, S., Baksh, S. N., Laeyendecker, O., Pekosz, A., Klein, S., Casadevall, A., Tobian, A. A., Hanley, D. F.
10.1101/2021.12.10.21267485 — Posted: 2021-12-21
Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults
Karron, R. A., Quesada, M. G., Schappell, E. A., Schmidt, S. D., Knoll, M. D., Hetrich, M. K., Veguilla, V., Doria-Rose, N., Dawood, F. S., SEARCh Study Team
10.1101/2021.12.20.21268034 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).